Pharma and FMCG firm Ozone Group is targeting a revenue of Rs 1,000 crore in next five years as it plans to focus on new therapeutic areas as well as strengthen existing distribution networks.
The company, which reported revenues of Rs 150 crore in the previous fiscal, said it would continue to develop and market new products both pharma and FMCG segments in order to meet its steep target.
"Country's economy is growing and so is the society. The growth has been fast in last decade as compared to the previous five decades. As for our target of touching Rs 1,000 crore in next five years, whatever needs to be done will be done," Ozone Group Managing Director SC Sehgal told PTI.
The company, which reported sales of Rs 75 crore and Rs 65 crore respectively from pharma and FMCG verticals in FY11, expects both to equally contribute in next five years.
"We are aiming to double sales from both verticals in the current fiscal itself. We expect them to contribute equally in the coming years," Sehgal said.
He added that the company planned to strengthen distribution network for its FMCG vertical which would help the company achieve the desired growth.
The company's 'No Marks' brand has been in the market since 2001. The company is also present in various therapeutic areas, including cardiology and diabetes.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
